Highly Stable Perovskite Solar Cells Based on the Efficient Interaction between Pb2+ and Cyano Groups of 4-Aminophthalonitrile.

Defects present on the top surface of perovskite films have a pronounced detrimental impact on the photovoltaic performance and stability of perovskite solar cells (PSCs). Consequently, the development of effective defect passivation strategies has become key in enhancing both the power conversion efficiency (PCE) and stability of PSCs. In this study, a small molecule material, 4-Aminophthalonitrile (4-APN), was introduced as a means to mitigate surface defects within perovskite films. Obviously, 4-APN effectively passivates the defects at grain boundaries by combining cyano groups (-C≡N) with Pb2+ , significantly reducing the density of defect states, inhibiting non-radiative recombination at the interface, and promoting the charge transfer efficiency from the perovskite layer to the hole transport layer. The 4-APN modification led to a significant upswing in the PCE, while concurrently bolstering the overall device stability. Importantly, the devices on 4-APN as passivation additive exhibited negligible performance degradation aging for 1200 h.

High-Fill-Factor Perovskite Solar Cells via Pseudohalide Salt Modification of the Substrate to Mitigate Nonradiative Recombination at the Interface.

The utilization of the sol-gel method for fabricating planar SnO2 as the electron transport layer (ETL) induces numerous defects on the SnO2 layer surface and perovskite film bottom, causing considerable deterioration of the device performance. Conventional inorganic salt-doped SnO2 precursor solutions used for passivation may cause incomplete substrate coverage due to the presence of inorganic salt crystals, further degrading the device performance. Here, a substrate modification approach involving the pretreatment of a fluorine-doped SnO2 (FTO) substrate with NH4PF6 is proposed. The interaction between PF6- ions and the FTO substrate enhances SnO2 film quality; excess PF6- ions decrease the number of defects on the film surface. NH4+ ions react with an -OH stabilizing agent in the SnO2 solution and are eliminated during annealing. The combined effects suppress nonradiative recombination and ion migration at the ETL-perovskite interface. The corresponding high-quality perovskite solar cells (PSCs) exhibit a fill factor of ∼0.825; PSC efficiency increases from 19.59% to 22.32%.

Enhancing the Efficiency of Perovskite Solar Cells by Bidirectional Modification of the Perovskite and Electron Transport Layer.

In perovskite solar cells (PSCs), the numerous defects present on the surface of the SnO2 electron transport layer (ETL) and the bottom of the perovskite film limit their power conversion efficiency (PCE) and stability. In view of this, a bidirectional modification strategy is designed using formamidine acetate (FAAc) to passivate the defects on the SnO2 ETL surface and bottom of the perovskite simultaneously. FA+ cations act on the harmful hydroxyl groups on the SnO2 ETL surface, whereas Ac- anions act on the iodine vacancy defect at the bottom of the perovskite. Because the interface defect is well passivated by FAAc, the interfacial charge recombination is restrained. This results in a significant increase in the filling factor of the PSC to ∼0.83 and the consequent increase in PCE to 23.05%, which considerably improves the stability. Bidirectional modification technology is an effective strategy for improving the PCE and stability of PSCs.

Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports.

BACKGROUND: Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. Apatinib has demonstrated encouraging antitumor activities. This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases. CASE SUMMARY: We report two patients with multiple brain micrometastases after failure of second-line treatment. Both patients had extracerebral metastases. When the patients took 250 mg/d apatinib orally, the intracerebral lesions disappeared. The extracerebral lesions were partially alleviated. Both patients had a progression-free survival of more than 12 mo and were still stable. The safety was good. The main adverse events (AEs) were mild hypertension and proteinuria, which could be controlled. CONCLUSION: Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment.